{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:12:29Z","timestamp":1790190749494,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005727","name":"Universidade de Coimbra","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jneuroim.2019.577080","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:44:12Z","timestamp":1571168652000},"page":"577080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Myasthenia gravis: State of the art and new therapeutic strategies"],"prefix":"10.1016","volume":"337","author":[{"given":"Eliana B.","family":"Souto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana R.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Martins-Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma B.","family":"Souto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lia M.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2019.577080_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2014.04.001","article-title":"The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review","volume":"55","author":"Bao","year":"2014","journal-title":"J. Autoimmun."},{"issue":"23","key":"10.1016\/j.jneuroim.2019.577080_bb0010","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of Ivig and Plex in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1212\/01.wnl.0000339103.08830.86","article-title":"Hla class ii allele analysis in musk-positive myasthenia gravis suggests a role for Dq5","volume":"72","author":"Bartoccioni","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jneuroim.2019.577080_bb0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(18)30467-8","article-title":"Thymectomy in myasthenia gravis: when, why, and how?","volume":"18","author":"Berrih-Aknin","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48\u201349","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cyto.2015.05.030","article-title":"Gm-Csf: an immune modulatory cytokine that can suppress autoimmunity","volume":"75","author":"Bhattacharya","year":"2015","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.jneuroim.2019.577080_bb0045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009167","article-title":"The role of Musk in synapse formation and neuromuscular disease","volume":"5","author":"Burden","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"5","key":"10.1016\/j.jneuroim.2019.577080_bb0050","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mus.880130507","article-title":"A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro","volume":"13","author":"Burges","year":"1990","journal-title":"Muscle Nerve"},{"issue":"160","key":"10.1016\/j.jneuroim.2019.577080_bb0055","article-title":"Neuromuscular junction impairment in amyotrophic lateral sclerosis: reassessing the role of acetylcholinesterase","volume":"9","author":"Campanari","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0065","article-title":"Thymectomy for non-thymomatous myasthenia gravis","volume":"10","author":"Cea","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"31","key":"10.1016\/j.jneuroim.2019.577080_bb0070","doi-asserted-by":"crossref","first-page":"8067","DOI":"10.1523\/JNEUROSCI.1515-16.2016","article-title":"Presynaptic deficits at neuromuscular junctions: a specific cause and potential target of axonal neuropathy in type 2 Charcot\u2013Marie\u2013tooth disease","volume":"36","author":"Chandhok","year":"2016","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0075","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/0972-2327.107690","article-title":"Electrophysiological study in neuromuscular junction disorders","volume":"16","author":"Cherian","year":"2013","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"11","key":"10.1016\/j.jneuroim.2019.577080_bb0085","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","article-title":"The search for new antigenic targets in myasthenia gravis","volume":"1275","author":"Cossins","year":"2012","journal-title":"Ann. NY Acad. Sci."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of Ox40 and Ox40l to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: a review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0115","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1086\/302059","article-title":"Mutation in the human acetylcholinesterase-associated collagen gene, Colq, is responsible for congenital Myasthenic syndrome with end-plate acetylcholinesterase deficiency (type Ic)","volume":"63","author":"Donger","year":"1998","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0120","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJM197801192980305","article-title":"Myasthenia gravis (first of two parts)","volume":"298","author":"Drachman","year":"1978","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jneuroim.2019.577080_bb0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/jnnp.43.7.601","article-title":"Mechanisms of acetylcholine receptor loss in myasthenia gravis","volume":"43","author":"Drachman","year":"1980","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2019.577080_bb0130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"issue":"6","key":"10.1016\/j.jneuroim.2019.577080_bb0135","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/mus.21306","article-title":"T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis","volume":"39","author":"Dubal","year":"2009","journal-title":"Muscle Nerve"},{"issue":"Pt 10","key":"10.1016\/j.jneuroim.2019.577080_bb0140","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-Musk antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to musk: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann. NY Acad. Sci."},{"issue":"7","key":"10.1016\/j.jneuroim.2019.577080_bb0150","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/08916931003674741","article-title":"Targeting lymphocyte co-stimulation: from bench to bedside","volume":"43","author":"Felix","year":"2010","journal-title":"Autoimmunity"},{"issue":"6","key":"10.1016\/j.jneuroim.2019.577080_bb0155","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2019.577080_bb0160","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"22","key":"10.1016\/j.jneuroim.2019.577080_bb0165","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-Agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jneuroim.2019.577080_bb0170","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2019.577080_bb0175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0180","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with Bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the myasthenia gravis Thymus: roles of Il-17 and Tnf-alpha","volume":"52","author":"Gradolatto","year":"2014","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0195","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards Subcommittee of the American Academy of neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2019.577080_bb0200","doi-asserted-by":"crossref","unstructured":"Gundisch, D., and C. Eibl. \"Nicotinic Acetylcholine Receptor Ligands, a Patent Review (2006\u20132011).\" no. 1744\u20137674 (Electronic).","DOI":"10.1517\/13543776.2011.637919"},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-musk antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0210","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1212\/NXI.0000000000000077","article-title":"Characterization of B cells in muscle-specific kinase antibody myasthenia gravis","volume":"2","author":"Guptill","year":"2015","journal-title":"Neurology(R) Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0215","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of Musk antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2019.577080_bb0220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2019.577080_bb0225","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1073\/pnas.74.7.3090","article-title":"Modulation of acetylcholine receptor by antibody against the receptor","volume":"74","author":"Heinemann","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0230","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1212\/WNL.0b013e3181ad53c2","article-title":"Seropositive myasthenia gravis: a nationwide epidemiologic study","volume":"73","author":"Heldal","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0235","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2019.577080_bb0240","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.4049\/jimmunol.1003412","article-title":"Antibody-mediated Coengagement of Fcgammariib and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus","volume":"186","author":"Horton","year":"2011","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.jneuroim.2019.577080_bb0245","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of Eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (regain): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0250","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. NY Acad. Sci."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0255","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase ii study of Eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0260","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/MN:25:1:079","article-title":"Clustering of nicotinic acetylcholine receptors: from the neuromuscular junction to interneuronal synapses","volume":"25","author":"Huh","year":"2002","journal-title":"Mol. Neurobiol."},{"issue":"51","key":"10.1016\/j.jneuroim.2019.577080_bb0265","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"Musk Igg4 autoantibodies cause myasthenia gravis by inhibiting binding between musk and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.jneuroim.2019.577080_bb0270","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.4049\/jimmunol.166.11.6893","article-title":"Blockade of Cd40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of Ctla-4","volume":"166","author":"Im","year":"2001","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.jneuroim.2019.577080_bb0275","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/ene.13688","article-title":"Reliability and Main findings of the flexible endoscopic evaluation of swallowing-tensilon test in patients with myasthenia gravis and dysphagia","volume":"25","author":"Im","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2776(10)05003-0","article-title":"Ox40-Ox40 ligand interaction in T-cell-mediated immunity and immunopathology","volume":"105","author":"Ishii","year":"2010","journal-title":"Adv. Immunol."},{"issue":"5","key":"10.1016\/j.jneuroim.2019.577080_bb0285","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4110\/in.2013.13.5.184","article-title":"Emerging co-signaling networks in T cell immune regulation","volume":"13","author":"Jung","year":"2013","journal-title":"Immune Netw."},{"issue":"5787","key":"10.1016\/j.jneuroim.2019.577080_bb0290","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0295","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00281-014-0427-7","article-title":"Targeting B cells and autoantibodies in the therapy of autoimmune diseases","volume":"36","author":"Kao","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0300","series-title":"Neuromuscular Disorders in Clinical Practice","author":"Katirji","year":"2013"},{"issue":"20","key":"10.1016\/j.jneuroim.2019.577080_bb0305","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","article-title":"Anti-Musk autoantibodies block binding of collagen Q to Musk","volume":"77","author":"Kawakami","year":"2011","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jneuroim.2019.577080_bb0310","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s40265-013-0080-9","article-title":"Abatacept: a review of its use in the management of rheumatoid arthritis","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0315","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.nmd.2018.12.011","article-title":"Evaluation and validation of sustained Upgaze combined with the ice-pack test for ocular myasthenia gravis in Asians","volume":"29","author":"Kee","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"5","key":"10.1016\/j.jneuroim.2019.577080_bb0320","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"Efns\/Ens guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0325","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for Agrin and forms a complex with Musk","volume":"135","author":"Kim","year":"2008","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.jneuroim.2019.577080_bb0330","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing Immunoadsorption and plasma exchange in Myasthenic crisis","volume":"26","author":"Kohler","year":"2011","journal-title":"J. Clin. Apher."},{"issue":"7","key":"10.1016\/j.jneuroim.2019.577080_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jneuroim.2019.577080_bb0340","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"Igg4 autoantibodies against muscle-specific kinase undergo fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0345","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1756285609356135","article-title":"Practical considerations on the use of rituximab in autoimmune neurological disorders","volume":"3","author":"Kosmidis","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0350","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.conb.2005.12.003","article-title":"Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost","volume":"16","author":"Kummer","year":"2006","journal-title":"Curr. Opin. Neurobiol."},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0355","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer Thymic changes in Musk antibody-positive than in Musk antibody-negative mg","volume":"57","author":"Leite","year":"2005","journal-title":"Ann. Neurol."},{"issue":"Pt 7","key":"10.1016\/j.jneuroim.2019.577080_bb0360","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"Igg1 antibodies to acetylcholine receptors in \u2018Seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.jneuroim.2019.577080_bb0365","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.4049\/jimmunol.1401392","article-title":"Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis","volume":"193","author":"Luo","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0370","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaut.2013.12.007","article-title":"T cell repertoire in Dq5-positive Musk-positive myasthenia gravis patients","volume":"52","author":"Marino","year":"2014","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.jneuroim.2019.577080_bb0375","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the Thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2019.577080_bb0380","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral Cd4+Cd25+ regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0385","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2004-829594","article-title":"Myasthenia gravis: diagnosis","volume":"24","author":"Meriggioli","year":"2004","journal-title":"Semin. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2019.577080_bb0390","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0395","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose Fk506 in the treatment of myasthenia gravis \u2013 a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0400","first-page":"674","article-title":"Immunomodulation by Ivig and the role of fc-gamma receptors: classic mechanisms of action after all?","volume":"5","author":"Nagelkerke","year":"2014","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0405","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clim.2005.02.010","article-title":"Regulation of immune and autoimmune responses by Icos-B7h interaction","volume":"115","author":"Nurieva","year":"2005","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0410","doi-asserted-by":"crossref","DOI":"10.1126\/stke.12pe3","article-title":"An emerging picture of synapse formation: a balance of two opposing pathways","volume":"1","author":"Ono","year":"2008","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0415","doi-asserted-by":"crossref","DOI":"10.1038\/srep13928","article-title":"Collagen Q and anti-musk autoantibody competitively suppress Agrin\/Lrp4\/Musk signaling","volume":"5","author":"Otsuka","year":"2015","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.jneuroim.2019.577080_bb0420","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1073\/pnas.040554597","article-title":"Oral Administration of a Dual Analog of two Myasthenogenic T cell epitopes Down-regulates experimental autoimmune myasthenia gravis in mice","volume":"97","author":"Paas-Rozner","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0425","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0430","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0435","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ncl.2018.01.010","article-title":"Diagnosis of myasthenia gravis","volume":"36","author":"Pasnoor","year":"2018","journal-title":"Neurol. Clin."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0440","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/j.seminhematol.2007.08.001","article-title":"Autologous stem cell transplantation in autoimmune diseases","volume":"44","author":"Passweg","year":"2007","journal-title":"Semin. Hematol."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0445","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2004-829593","article-title":"The epidemiology of myasthenia gravis","volume":"24","author":"Phillips","year":"2004","journal-title":"Semin. Neurol."},{"issue":"8","key":"10.1016\/j.jneuroim.2019.577080_bb0450","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/ni.2939","article-title":"Type I and type ii fc receptors regulate innate and adaptive immunity","volume":"15","author":"Pincetic","year":"2014","journal-title":"Nat. Immunol."},{"issue":"Pt 20","key":"10.1016\/j.jneuroim.2019.577080_bb0455","first-page":"3629","article-title":"Titin force is enhanced in actively stretched skeletal muscle","volume":"217","author":"Powers","year":"2014","journal-title":"J. Exp. Biol."},{"issue":"5","key":"10.1016\/j.jneuroim.2019.577080_bb0460","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","article-title":"Myasthenia gravis and the neuromuscular junction","volume":"26","author":"Querol","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0465","first-page":"939520","article-title":"B-cell-activating factor and autoimmune myasthenia gravis","volume":"2011","author":"Ragheb","year":"2011","journal-title":"Autoimmune Dis."},{"issue":"10","key":"10.1016\/j.jneuroim.2019.577080_bb0470","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0475","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12883-017-0891-5","article-title":"Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: does abnormal jitter predict response to treatment?","volume":"17","author":"Rakocevic","year":"2017","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0480","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","article-title":"A genome-wide association study of myasthenia gravis","volume":"72","author":"Renton","year":"2015","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0485","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis: reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2019.577080_bb0490","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi","year":"2007","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2019.577080_bb0495","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","article-title":"Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis","volume":"259","author":"Romi","year":"2012","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.jneuroim.2019.577080_bb0500","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0505","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/mus.23488","article-title":"Granulocyte macrophage colony-stimulating factor treatment of a patient in Myasthenic crisis: effects on regulatory T cells","volume":"46","author":"Rowin","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2019.577080_bb0510","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2008.04.038","article-title":"How myasthenia gravis alters the safety factor for neuromuscular transmission","volume":"201\u2013202","author":"Ruff","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0515","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising Cd4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.jneuroim.2019.577080_bb0520","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase iii, randomized trial of mycophenolate Mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0525","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for Management of Myasthenia Gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jneuroim.2019.577080_bb0530","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.clinph.2019.04.005","article-title":"Guidelines for Single Fiber Emg","volume":"130","author":"Sanders","year":"2019","journal-title":"Clin. Neurophysiol."},{"issue":"5","key":"10.1016\/j.jneuroim.2019.577080_bb0535","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"Il-17-producing Cd4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.jneuroim.2019.577080_bb0540","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"Baff, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(97)00232-3","article-title":"Nasal Administration of Multiple Antigens Suppresses Experimental Autoimmune Myasthenia Gravis, encephalomyelitis and neuritis","volume":"155","author":"Shi","year":"1998","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0550","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J. Clin. Neuromuscul. Dis."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0555","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/mus.10294","article-title":"Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro","volume":"27","author":"Skeie","year":"2003","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.jneuroim.2019.577080_bb0560","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0565","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1468-2494.2008.00433.x","article-title":"Cosmetic features and applications of lipid nanoparticles (Sln, Nlc)","volume":"30","author":"Souto","year":"2008","journal-title":"Int. J. Cosmet. Sci."},{"issue":"1","key":"10.1016\/j.jneuroim.2019.577080_bb0570","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1749-6632.1976.tb47685.x","article-title":"Single-muscle-fiber recording of the jitter phenomenon in patients with myasthenia gravis and in members of their families","volume":"274","author":"St\u00e5lberg","year":"1976","journal-title":"Ann. NY Acad. Sci."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0575","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.23951","article-title":"Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis","volume":"49","author":"Sun","year":"2014","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.jneuroim.2019.577080_bb0580","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune targets of heart and skeletal muscles in myasthenia gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2019.577080_bb0585","first-page":"740583","article-title":"Three types of Striational antibodies in myasthenia gravis","volume":"2011","author":"Suzuki","year":"2011","journal-title":"Autoimmune Dis."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0590","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Antititin antibody in early- and late-onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0595","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0600","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4049\/jimmunol.1401329","article-title":"B10 cells: a functionally defined regulatory B cell subset","volume":"194","author":"Tedder","year":"2015","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.jneuroim.2019.577080_bb0605","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"Cd20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol. Today"},{"key":"10.1016\/j.jneuroim.2019.577080_bb0610","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1749-6632.2012.06840.x","article-title":"Functional defect in regulatory T cells in myasthenia gravis","volume":"1274","author":"Thiruppathi","year":"2012","journal-title":"Ann. NY Acad. Sci."},{"issue":"12","key":"10.1016\/j.jneuroim.2019.577080_bb0615","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2019.577080_bb0620","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2007.02.020","article-title":"A prospective study assessing the utility of Cogan\u2019s lid twitch sign in patients with isolated unilateral or bilateral ptosis","volume":"256","author":"Van Stavern","year":"2007","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0625","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4049\/jimmunol.1601415","article-title":"Dysregulation of B cell repertoire formation in myasthenia gravis patients revealed through deep sequencing","volume":"198","author":"Vander Heiden","year":"2017","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0630","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1212\/01.wnl.0000173031.56429.04","article-title":"Primary Cns lymphoma complicating treatment of myasthenia gravis with mycophenolate Mofetil","volume":"65","author":"Vernino","year":"2005","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jneuroim.2019.577080_bb0635","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.jneuroim.2019.577080_bb0640","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/eji.201445101","article-title":"With a little help from my old T cell: memory follicular T helper cells driving autoimmunity?","volume":"44","author":"Winkler","year":"2014","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.jneuroim.2019.577080_bb0645","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.410150615","article-title":"Azathioprine in the treatment of myasthenia gravis","volume":"15","author":"Witte","year":"1984","journal-title":"Ann. Neurol."},{"issue":"6\u20138","key":"10.1016\/j.jneuroim.2019.577080_bb0650","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.mod.2012.09.004","article-title":"The neuromuscular junction: selective remodeling of synaptic regulators at the nerve\/muscle Interface","volume":"130","author":"Witzemann","year":"2013","journal-title":"Mech. Dev."},{"issue":"2","key":"10.1016\/j.jneuroim.2019.577080_bb0655","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.trsl.2014.10.010","article-title":"Anticomplement C5 therapy with Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"165","author":"Wong","year":"2015","journal-title":"Transl. Res."},{"issue":"4","key":"10.1016\/j.jneuroim.2019.577080_bb0660","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2019.577080_bb0665","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.imlet.2013.07.005","article-title":"The Cd40\/Cd40l system: a new therapeutic target for disease","volume":"153","author":"Zhang","year":"2013","journal-title":"Immunol. Lett."},{"issue":"3","key":"10.1016\/j.jneuroim.2019.577080_bb0670","article-title":"Autoantibodies to Agrin in myasthenia gravis patients","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jneuroim.2019.577080_bb0675","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.jneuroim.2019.577080_bb0680","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.autrev.2013.03.002","article-title":"Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens","volume":"12","author":"Zisimopoulou","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2019.577080_bb0685","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","article-title":"Collagen Q \u2013 a potential target for autoantibodies in myasthenia gravis","volume":"348","author":"Zoltowska Katarzyna","year":"2015","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572819304539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572819304539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:36:19Z","timestamp":1759048579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572819304539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":137,"alternative-id":["S0165572819304539"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577080","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis: State of the art and new therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577080"}}